nuclear medicine
Recently Published Documents


TOTAL DOCUMENTS

8079
(FIVE YEARS 1112)

H-INDEX

62
(FIVE YEARS 14)

Author(s):  
Kenji Hirata ◽  
Hiroyuki Sugimori ◽  
Noriyuki Fujima ◽  
Takuya Toyonaga ◽  
Kohsuke Kudo

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Simon Klingler ◽  
Jason P. Holland

AbstractClinical production of 89Zr-radiolabeled antibodies (89Zr-mAbs) for positron emission tomography imaging relies on the pre-conjugation of desferrioxamine B (DFO) to the purified protein, followed by isolation and characterization of the functionalized intermediate, and then manual radiosynthesis. Although highly successful, this route exposes radiochemists to a potentially large radiation dose and entails several technological and economic hurdles that limit access of 89Zr-mAbs to just a specialist few Nuclear Medicine facilities worldwide. Here, we introduce a fully automated synthesis box that can produce individual doses of 89Zr-mAbs formulated in sterile solution in < 25 min starting from [89Zr(C2O4)4]4– (89Zr-oxalate), our good laboratory practice-compliant photoactivatable desferrioxamine-based chelate (DFO-PEG3-ArN3), and clinical-grade antibodies without the need for pre-purification of protein. The automated steps include neutralization of the 89Zr-oxalate stock, chelate radiolabeling, and light-induced protein conjugation, followed by 89Zr-mAb purification, formulation, and sterile filtration. As proof-of-principle, 89ZrDFO-PEG3-azepin-trastuzumab was synthesized directly from Herceptin in < 25 min with an overall decay-corrected radiochemical yield of 20.1 ± 2.4% (n = 3), a radiochemical purity > 99%, and chemical purity > 99%. The synthesis unit can also produce 89Zr-mAbs via the conventional radiolabeling routes from pre-functionalized DFO-mAbs that are currently used in the clinic. This automated method will improve access to state-of-the-art 89Zr-mAbs at the many Nuclear Medicine and research institutions that require automated devices for radiotracer production.


Author(s):  
Sofia C. Vaz ◽  
Judit A. Adam ◽  
Roberto C. Delgado Bolton ◽  
Pierre Vera ◽  
Wouter van Elmpt ◽  
...  

Abstract Purpose 2-[18F]FDG PET/CT is of utmost importance for radiation treatment (RT) planning and response monitoring in lung cancer patients, in both non-small and small cell lung cancer (NSCLC and SCLC). This topic has been addressed in guidelines composed by experts within the field of radiation oncology. However, up to present, there is no procedural guideline on this subject, with involvement of the nuclear medicine societies. Methods A literature review was performed, followed by a discussion between a multidisciplinary team of experts in the different fields involved in the RT planning of lung cancer, in order to guide clinical management. The project was led by experts of the two nuclear medicine societies (EANM and SNMMI) and radiation oncology (ESTRO). Results and conclusion This guideline results from a joint and dynamic collaboration between the relevant disciplines for this topic. It provides a worldwide, state of the art, and multidisciplinary guide to 2-[18F]FDG PET/CT RT planning in NSCLC and SCLC. These practical recommendations describe applicable updates for existing clinical practices, highlight potential flaws, and provide solutions to overcome these as well. Finally, the recent developments considered for future application are also reviewed.


2022 ◽  
Vol 8 ◽  
Author(s):  
Mitchel R. Stacy

Peripheral arterial disease (PAD) is an atherosclerotic disorder of non-coronary arteries that is associated with vascular stenosis and/or occlusion. PAD affecting the lower extremities is characterized by a variety of health-related consequences, including lifestyle-limiting intermittent claudication, ulceration of the limbs and/or feet, increased risk for lower extremity amputation, and increased mortality. The diagnosis of lower extremity PAD is typically established by using non-invasive tests such as the ankle-brachial index, toe-brachial index, duplex ultrasound, and/or angiography imaging studies. While these common diagnostic tools provide hemodynamic and anatomical vascular assessments, the potential for non-invasive physiological assessment of the lower extremities has more recently emerged through the use of magnetic resonance- and nuclear medicine-based approaches, which can provide insight into the functional consequences of PAD-related limb ischemia. This perspectives article specifically highlights and discusses the emerging applications of clinical nuclear medicine techniques for molecular imaging investigations in the setting of lower extremity PAD.


2022 ◽  
Vol 20 (4) ◽  
pp. 131-142
Author(s):  
R. V. Zelchan ◽  
A. A. Medvedeva ◽  
O. D. Bragina ◽  
A. N. Ribina ◽  
A. I. Ryabova ◽  
...  

The review analyzes the global experience in the application of nuclear medicine techniques for diagnosis of tumors and non-tumor pathologies of the brain. The main groups of radiopharmaceuticals currently used for imaging of malignant brain tumors and diagnosis of cognitive impairments and neurotransmitter system disturbances by means of single-photon emission computed tomography and positron emission tomography are described.Modern approaches to the application of methods for radionuclide diagnosis in neuro-oncology and neurology are compared, and the main trends in production of new, more specific radiopharmaceuticals for visualizing brain tumors of various degrees of malignancy and diagnosing non-tumor pathologies of the brain are described. The review discusses the advantages and disadvantages of currently used techniques and radiopharmaceuticals for imaging of central nervous system disorders, depending on the clinical situation and specific diagnostic tasks.In addition, the review presents consolidated recommendations of the leading scientific schools in neuro-oncology on the use of nuclear medicine techniques in patients with brain tumors at the stages of treatment and follow-up. The presented article examines the experience of domestic scientific schools in the development of radiopharmaceuticals for neuro-oncology. The features of the development and use of new radiopharmaceuticals in patients with brain tumors and neurodegenerative diseases are highlighted. The review is based on the analysis of literature included in the Scopus, Web of Science, MedLine, The Cochrane Library, EMBASE, Global Health, and RSCI databases. 


2022 ◽  
Author(s):  
Diana Melis ◽  
Andrew Burgoyne ◽  
Maarten Ooms ◽  
Gilles Gasser

Targeted radionuclide therapy (TRNT) is an ever-expanding field of nuclear medicine that provides a personalised approach to cancer treatment while limiting toxicity to normal tissues. It involves the radiolabelling of...


2022 ◽  
pp. 67-73
Author(s):  
Aitor Gallastegui
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document